LBT-3627: MODULATING TREGS VIA VPAC2 ACTIVATION RESULTING IN A NOVEL IMMUNOMODULATORY DISEASE-MODIFYING APPROACH TO ALS TREATMENT

Longevity Biotech, Inc., Philadelphia PA

Investigators